All Type of News
KFDA approves new type 2 diabetic agent
The Korea Food and Drug Administration said Monday it has approved Onglyza (saxagliptin), a dipeptidyl peptidase-4 (DPP4) inhibitor.
Developed by Bristol-Myers Squibb Company and AstraZeneca, Onglyza is indicated ...
Drugmakers gear up for sports marketing
Korean pharmaceutical companies are putting more and more efforts into sports marketing in a bold step to raise OTC sales in domestic market. Such moves are likely to be reinforced further as health is the best motto ...
KFDA to reveal all excipients of parenteral preparations
The Korea Foods and Drug Administration plans to disclose all excipients to be used in parenteral preparation and eye/ear drop as the component might affect the safety and efficacy of the finished product depending on...
HIRA discloses screening details of 44 treatments and tests
The Health Insurance Review Agency has revealed a total of 44 screening criteria for 44 treatments and tests to be reimbursed under health insurance scheme.
HIRA officials reiterated that the disclosure of such scr...
Green Cross develops fourth natural medicine
Green Cross Corp. says its natural drug for the treatment of osteoarthritis drug ‘Shinbaro’ has been recently approved by the Korea Food and Drug Administration.
The company said Shinbaro is Korea’s fourth homegrow...
New anticancer medicine Jevtana designated as orphan drug
Sanofi-aventis Korea said that the Korea Food and Drug Administration has designated Jevtana (cabazitaxel) Injection as an orphan drug.
The company also said Jevtana is expected to be available as a marketed produc...
Pharmacists get angry over poor DUR system
A number of pharmacists in Seoul could not perform the dispensing business due to technical setbacks of the Drug Utilization Review (DUR) system last Saturday.
Pharmacists tried to perform the DUR program from 11 a...
Ilyang to spur vaccine development
In an effort to develop a variety of vaccines for influenza, food and mouth disease, dengue fever and rabies, Ilyang Pharmaceutical Co, signed a memorandum of understanding with Taiwan based Medigen Biotechnology Corp...
Release of aseptic preparations to be shortened
Amino infusion makers will be able to release their products in an earlier period.
The Korea Food and Drug Administration says it will introduce a parametric release system, under which aseptic preparations could b...
ARB drugs surpass calcium antagonists
The market share of angiotensin-2 receptor blocks (ARB), such as Almetec and Cozzar, has gained momentum, outpacing the former No. 1 drug on the antihypertensive market, Norvasc, by a wide margin.
ARB drugs account...
